These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36309864)

  • 21. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroid-associated ophthalmopathy in Iranian patients.
    Kashkouli MB; Jam S; Sabzvari D; Ketabi N; Azarinia S; SeyedAlinaghi S; Mofid A
    Acta Med Iran; 2011; 49(9):612-8. PubMed ID: 22052145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial.
    Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S;
    Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab for thyroid eye disease.
    Silkiss RZ; Reier A; Coleman M; Lauer SA
    Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life in thyroid eye disease: impact of quality of care.
    Estcourt S; Quinn AG; Vaidya B
    Eur J Endocrinol; 2011 May; 164(5):649-55. PubMed ID: 21367964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life in patients with thyroid eye disease.
    Bahmani-Kashkouli M; Pakdel F; Astaraki A; Hashemi M; Honarbakhsh Y; Mirarmandehi B; Jam S
    J Ophthalmic Vis Res; 2009 Jul; 4(3):164-8. PubMed ID: 23198067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring Health-Related Quality of Life in Thyroid Eye Disease.
    Sharma A; Stan MN; Rootman DB
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S27-S35. PubMed ID: 36346683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbial Keratitis in Thyroid Eye Disease: Clinical Features, Microbiological Profile, and Treatment Outcome.
    Naik MN; Vasanthapuram VH; Joseph J; Murthy SI
    Ophthalmic Plast Reconstr Surg; 2019; 35(6):543-548. PubMed ID: 30844912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
    Krassas GE
    Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective study of pediatric thyroid eye disease: the Asian experience.
    Sim B; Chng CL; Audrey C; Seah LL
    Orbit; 2022 Feb; 41(1):69-78. PubMed ID: 33059514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular Hypertension, Glaucoma or Compressive Neuropathy in Patient with Active TED.
    Stoyanova NS; Konareva-Kostianeva MI; Mitkova-Hristova VT
    Folia Med (Plovdiv); 2020 Jun; 62(2):418-423. PubMed ID: 32666771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease.
    Fayers T; Fayers PM; Dolman PJ
    Orbit; 2016 Dec; 35(6):328-334. PubMed ID: 27599688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severity of thyroid eye disease and type-2 diabetes mellitus: Is there a correlation?
    Ramamurthy LB; Rangarajan V; Srirao N; Malini B; Bansal R; Yuvarajan K
    Indian J Ophthalmol; 2020 Jun; 68(6):1127-1131. PubMed ID: 32461446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Thermal Camera in the Assessment of Thyroid Eye Disease Activity.
    Prpic A; Kasumovic A; Guarro IG; Matoc I; Mirosevic G; Zrinscak O; Ivekovic R; Vickovic IP; Loncar VL; Vatavuk Z; Sabol I
    Acta Inform Med; 2023; 31(4):260-264. PubMed ID: 38379681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.
    Yu CY; Ford RL; Wester ST; Shriver EM
    Indian J Ophthalmol; 2022 Jul; 70(7):2335-2345. PubMed ID: 35791115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.
    Ponto KA; Diana T; Binder H; Matheis N; Pitz S; Pfeiffer N; Kahaly GJ
    J Endocrinol Invest; 2015 Jul; 38(7):769-77. PubMed ID: 25736545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.